NBDF showcases a wide array of findings from the latest in bleeding disorders research at our annual Bleeding Disorders Conference.
Reduced Polyethylene Glycol–Conjugated B-Domain–Deleted Factor VIII (PEG-BDD-FVIII) Clearance: Selective PEG Steric Modulation Without Affecting Potency
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
Effect of hemophilia treatment center monitoring on bleeding rates
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
The Effects of Hemophilia on Socialization
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Intervention of Mexicans children and teenagers with hemophilia for their social integration
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Quantitative research into people with hemophilia and caregiver perceptions of pre-filled solvent syringe (MixPro®)
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Personalization of Treatment Regimens for Physically Active Patients: A Comparison of Factor VIII and Extended Half-life Treatment Regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Pharmacist/Provider Collaboration needed to Optimize Dosing Regimens in Order to Reduce Bleed Rates in Hemophilia A Patients on Prophylaxis Regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Cost of Treating Thrombotic Events in a US Population of Von Willebrand Disease Patients
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
Interim results of the B-YOND study evaluating long-term safety and efficacy of recombinant factor IX Fc (rFIXFc) in children with severe hemophilia B
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
The impact of missing one or two infusions per month: a comparison of rFVIII and rFVIIIFc regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
SPINART 3-Year Analyses: Patient- and Joint-Level Changes in Colorado Adult Joint Assessment Scale and Magnetic Resonance Imaging Scores With Bayer’s Sucrose-Formulated Recombinant Factor VIII (rFVIII-FS) in Adolescents and Adults
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Leading an Active Lifestyle with Hemophilia B: Estimating the Bleeding Risk with Different FIX Treatment Regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
A Half-Life Extended Fusion Peptide Inhibitor of TFPI Improves Hemostasis in Preclinical Models of Hemophilia
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
Pharmacokinetics, safety, and efficacy of pdFX, a new high-purity factor X concentrate: a phase 3 study in patients with moderate or severe hereditary factor X deficiency
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Patient Satisfaction with US Hemophilia Treatment Centers 2015: National Results
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
My Life, Our Future: A “Genetics Day” to Facilitate Efficient Enrollment
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Long-term safety and efficacy of recombinant factor VIII Fc (rFVIIIFc) for the treatment of severe hemophilia A: United States subgroup interim analysis of the ASPIRE study
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
SPACE (Study of Prophylaxis ACtivity, and Effectiveness): An interim descriptive analysis of patient activity levels and participation
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910 in Japanese hemophilia A patients with and without FVIII inhibitors: Interim results of the extension study of a phase I study
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Update on a phase 1/2 open-label trial of BAX 335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials